Our ambition has been to design a neuro-oncology service which treats the whole patient, not just the tumour. The incidence of brain metastasis is increasing, due to better imaging surveillance and improved systemic treatment of extracranial primary disease – up to 30 per cent of cancer patients are likely to develop a brain metastasis. Conventional radiotherapy treatments often lead to cognitive deterioration, with no benefit in terms of survival, but innovative techniques such as stereotactic radiosurgery (SRS) are offering improved quality of life outcomes.
We offer a comprehensive diagnostic service including 3TMRI, PET/CT and genetics and genomic testing and functional MRI (fMRI).
A non–invasive MRI technique, fMRI is used to locate eloquent brain tissue related to speech, vision, movement, etc., to guide neurosurgical planning and tailor surgery for intrinsic brain tumours to avoid neurological deficit and improve patient outcome.
We have now adopted this technique into our neuro-oncology pathway. With the increasing neuro-oncological benefits of surgery for brain tumours, fMRI offers potential further applications to measure brain recovery processes, to optimally stage and monitor treatments. We are the first private service to offer this to our patients in the UK.
In addition, patients are offered a complementary MRI technique called Diffusion tractography imaging. This imaging scan provides additional information about the location of important brain pathways for speech, movement, vision and other behaviours important for patient quality of life.
Our Oxford centre is a centre of excellence for Stereotactic Radiosurgery (SRS) – often described as brain-sparing surgery, SRS has revolutionised the treatment of small tumour sites.
Using a latest-generation linear accelerator, together with ExacTrac, a fast and highly accurate X-Ray system for patient positioning, allows greater precision and reduced treatment times – as little as 20 minutes. Our London centre houses a Gamma Knife for SRS procedures.
We provide a full range of systemic chemotherapies in our private, individual chemotherapy suites. This includes: iQemo management platform; nurses on call 24/7, acute pathways and a dedicated, on-site resident medical officer.
In a world-first partnership with Brainlab and Magic Leap, we have introduced mixed reality to interpret and visualise medical data in 3D format. Mixed reality viewers are used by our doctors to help explain their brain scan, the surgical plans and possible outcomes – offering reassurance to patients and unravelling some of the complexity of treatment in neuro-oncology.